Midterm results after treatment of gram-positive deep sternal wound infections with daptomycin for cardiac surgery patients
© Ort et al.; licensee BioMed Central Ltd. 2013
Received: 26 October 2012
Accepted: 23 January 2013
Published: 26 January 2013
Daptomycin in combination with surgical therapy has shown to be effective for treatment of deep sternal wound infection in cardiac surgery. However, till now midterm results in terms of re-infection or re-operation in patients who were successfully treated with daptomycin for gram-positive deep sternal wound infection are not published. Herein, we present midterm results in patients treated successfully with daptomycin after cardiac surgery.
KeywordsCardiac surgery Deep sternal infection Antibiotic treatment Daptomycin Midterm outcome
This follow up study includes 23 patients. These patients were treated in the past with daptomycin combined with multiple surgeries for deep sternal wound infection (DSWI) due to gram-positive organisms. The initial surveillance was achieved in 100% and wound healing was successfully established in all patients at the time of discharge for the initial clinical course . After discharge, all patients were followed up in terms of mortality, re-infection, and re-operation.
None of the patients were lost to follow up and follow-up time ranged from 3–42 months (mean 26 months, cumulative 598 patient-months). Four patients (17%) died during the follow up. Three of them died within 3 months of discharge; one due to mitral valve endocarditis, one due to urosepsis, and cause of death could not be established in one. The last patient died after 24 months and cause of death could not be established in him as well. No documented wound complications occurred in any of these patients from the time of discharge till their death.
Two patients (8.5%) after discharge developed superficial wound complications, which were treated surgically. The first patient had a coronary artery bypass grafting and postoperatively developed a DSWI with a Staphylococcus aureus and was discharged after 4 weeks in a good clinical condition. Thirty-two months after discharge, he developed superficial wound dehiscence, however without any microbial infection.
DSWI after cardiac surgery with sternotomy is still a serious surgical challenge. Several treatment options are described in the literature to deal with this complication. A wide range of strategies have been proposed for the treatment of DSWI, including an intense course of directed antibiotic therapy together with a series of debridements and multiple dressing changes . Interestingly, data on the optimal antibiotic management or duration of therapy for DSWI is scarce. Daptomycin has shown to be effective combined with multiple surgeries for treatment of DSWI in cardiac surgery [1, 3, 4]. However, up till now, no study has shown midterm results in terms of re-infection or re-operation for patients who were successfully treated with daptomycin for gram-positive DSWI.
We have published our results of prospective study about treatment of gram-positive DSWI with daptomycin for cardiac surgery patients performed between February 2009 and September 2010 . Twenty-three consecutive patients with post-sternotomy mediastinitis from gram-positive organisms (out of 1574 primary sternotomies) were identified and treated with intravenous daptomycin with acceptable mortality and morbidity. However, the major drawback of our study was limited observation period lacking any information regarding post-discharge re-infection or re-operation.
Herein, we present our results of discharged patient’s outcome which were treated successfully with daptomycin after cardiac surgery in a midterm follow up.
We had no recurrence of DSWI, which is observed occasionally after cardiac surgery . However, we had one case with superficial wound infection with Staphylococcus aureus methicillin susceptible which was treated successfully again with daptomycin.
Also, the mortality in the follow up in patients with DSWI was not different compared to contemporary study . This follow up study confirms that daptomycin can be considered as a viable treatment option for surgical management of gram-positive DSWI after cardiac surgery combined with surgical therapy. Our series presents several limitations; mainly lack of randomization and a small cohort. Further studies are warranted to confirm our single centre experience with daptomycin in treatment of gram-positive DSWI.
The authors gratefully thank Mrs. Dagmar Sitte for her expert assistance at wound treatment.
- Popov AF, Schmitto JD, Jebran AF, Bireta C, Friedrich M, Rajaruthnam D, Coskun KO, Braeuer A, Hinz J, Tirilomis T, Schoendube FA: Treatment of gram-positive deep sternal wound infections in cardiac surgery–experiences with daptomycin. J Cardiothorac Surg. 2011, 6: 112-10.1186/1749-8090-6-112.View ArticlePubMedPubMed CentralGoogle Scholar
- Sjogren J, Malmsjo M, Gustafsson R, Ingemansson R: Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum assisted closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg. 2006, 30: 898-905. 10.1016/j.ejcts.2006.09.020.View ArticlePubMedGoogle Scholar
- Popov AF, Schmitto JD, Tirilomis T, Bireta C, Coskun KO, Mokashi SA, Emmert A, Friedrich M, Wiese CH, Schoendube FA: Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery. J Cardiothorac Surg. 2010, 5: 57-PubMedPubMed CentralGoogle Scholar
- Weis F, Heyn J, Hinske CL, Vogt F, Weis M, Kur F, Hagl C, Beiras-Fernandez A: Daptomycin as supportive treatment option in patients developing mediastinitis after open cardiac surgery. J Cardiothorac Surg. 2012, 7 (1): 81-10.1186/1749-8090-7-81.View ArticlePubMedPubMed CentralGoogle Scholar
- Risnes I, Abdelnoor M, Almdahl SM, Svennevig JL: Mediastinitis after coronary artery bypass grafting risk factors and long-term survival. Ann Thorac Surg. 2010, 89 (5): 150-View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.